These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36359470)

  • 61. Serum integrative omics reveals the landscape of human diabetic kidney disease.
    Liu S; Gui Y; Wang MS; Zhang L; Xu T; Pan Y; Zhang K; Yu Y; Xiao L; Qiao Y; Bonin C; Hargis G; Huan T; Yu Y; Tao J; Zhang R; Kreutzer DL; Zhou Y; Tian XJ; Wang Y; Fu H; An X; Liu S; Zhou D
    Mol Metab; 2021 Dec; 54():101367. PubMed ID: 34737094
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Mulder S; Hammarstedt A; Nagaraj SB; Nair V; Ju W; Hedberg J; Greasley PJ; Eriksson JW; Oscarsson J; Heerspink HJL
    Diabetes Obes Metab; 2020 Jul; 22(7):1157-1166. PubMed ID: 32115853
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease.
    Zhang H; Hu W; Zhang G
    Int Urol Nephrol; 2020 Aug; 52(8):1517-1522. PubMed ID: 32458209
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
    Huang B; Wen W; Ye S
    Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy.
    Zhang F; Guo R; Cui W; Wang L; Xiao J; Shang J; Zhao Z
    Ren Fail; 2021 Dec; 43(1):980-992. PubMed ID: 34157945
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
    Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploration of Noninvasive Detection of Advanced Glycation End Products in the Lens to Screen for Diabetic Kidney Disease.
    Zhang XM; Gao Y; Yang MX; Zheng XD; Zhang R; Wu YY; Zeng M; Yang Q; Yu ZY; Liu J; Zha BB; Yang B
    Front Endocrinol (Lausanne); 2022; 13():892070. PubMed ID: 35846309
    [TBL] [Abstract][Full Text] [Related]  

  • 68. C3c deposition predicts worse renal outcomes in patients with biopsy-proven diabetic kidney disease in type 2 diabetes mellitus.
    Li MR; Sun ZJ; Chang DY; Yu XJ; Wang SX; Chen M; Zhao MH
    J Diabetes; 2022 Apr; 14(4):291-297. PubMed ID: 35322566
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 5-Hydroxymethylcytosine profiles in plasma cell-free DNA reflect molecular characteristics of diabetic kidney disease.
    Chu JL; Bi SH; He Y; Ma RY; Wan XY; Wang ZH; Zhang L; Zheng MZ; Yang ZQ; Du LW; Maimaiti Y; Biekedawulaiti G; Duolikun M; Chen HY; Chen L; Li LL; Tie L; Lin J
    Front Endocrinol (Lausanne); 2022; 13():910907. PubMed ID: 35966076
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease.
    Xiao X; Zhang J; Ji S; Qin C; Wu Y; Zou Y; Yang J; Zhao Y; Yang Q; Liu F
    Front Endocrinol (Lausanne); 2022; 13():1026995. PubMed ID: 36277729
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of Urinary Sodium Excretion and Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.
    Huang Y; Liu W; Liu J; Guo D; Zhang P; Liu D; Lin J; Yang L; Zhang H; Xue Y
    Front Endocrinol (Lausanne); 2021; 12():772073. PubMed ID: 34777262
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients.
    Fathy SA; Mohamed MR; Ali MAM; El-Helaly AE; Alattar AT
    Biomarkers; 2019 Feb; 24(1):43-55. PubMed ID: 30015512
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The hidden diabetic kidney disease in a university hospital-based population: a real-world data analysis.
    Marques M; López-Sánchez P; Tornero F; Gargantilla P; Maroto A; Ortiz A; Portolés J
    Clin Kidney J; 2022 Oct; 15(10):1865-1871. PubMed ID: 36158147
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
    Hu Y; Li TT; Zhou W; Lu TT; Li FF; Ding B; Liu BL; Xie XJ; Ma JH
    Diabetes Res Clin Pract; 2019 Apr; 150():194-201. PubMed ID: 30904742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease.
    Zhao T; Zhang H; Zhao T; Zhang X; Lu J; Yin T; Liang Q; Wang Y; Luo G; Lan H; Li P
    J Pharm Biomed Anal; 2012 Feb; 60():32-43. PubMed ID: 22153801
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metabolomic biomarkers in diabetic kidney diseases--A systematic review.
    Zhang Y; Zhang S; Wang G
    J Diabetes Complications; 2015; 29(8):1345-51. PubMed ID: 26253264
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
    Willis M; Nilsson A; Kellerborg K; Ball P; Roe R; Traina S; Beale R; Newell I
    Diabetes Ther; 2021 Jan; 12(1):313-328. PubMed ID: 33263893
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy.
    Weiss N; Barbier Saint Hilaire P; Colsch B; Isnard F; Attala S; Schaefer A; Amador MD; Rudler M; Lamari F; Sedel F; Thabut D; Junot C
    J Hepatol; 2016 Dec; 65(6):1120-1130. PubMed ID: 27520878
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.
    Jiang H; Shao X; Jia S; Qu L; Weng C; Shen X; Wang Y; Huang H; Wang Y; Wang C; Feng S; Wang M; Feng H; Geekiyanage S; Davidson AJ; Chen J
    Cell Physiol Biochem; 2019; 52(2):156-171. PubMed ID: 30816665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.